Skip to main content
logo
Hemab Therapeutics Holdings logo
Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
31.62
+0.73 (2.36%)
Oct 9, 2026, 4:00 PM EDT - Market closed

COAG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-83.24-63.91-48.71
Depreciation & Amortization
0.30.30.25
Loss (Gain) From Sale of Investments
-2.57-0.77-1.28
Stock-Based Compensation
4.392.011.91
Other Operating Activities
0.48-0.460.79
Change in Accounts Payable
2.512.580.91
Change in Other Net Operating Assets
0.8-1.220.54
Operating Cash Flow
-77.33-61.48-45.59
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.14-0.02-0.28
Investment in Securities
-220.14-81.4762.19
Investing Cash Flow
-220.27-81.4861.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Repaid
--0.12-0.1
Net Debt Issued (Repaid)
-0.11-0.12-0.1
Other Financing Activities
-0.48-0.48-
Financing Cash Flow
473.48156.3-0.1

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Foreign Exchange Rate Adjustments
00.22-
Net Cash Flow
175.8813.5716.21

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-77.47-61.49-45.87
Free Cash Flow Growth
---
Free Cash Flow Per Share
-9.36-65.00-48.49
Levered Free Cash Flow
--39.59-
Unlevered Free Cash Flow
--39.59-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash Interest Paid
00.010.02
Cash Income Tax Paid
-0.170.09
Change in Working Capital
3.311.361.45
SEC Filings: 10-K · 10-Q